1203 results about "Nausea" patented technology

A system and method for treating nausea and vomiting are provided, including one or more electrodes (10, 12) applied on or under the skin, the electrodes being connected to an external current source (34). The electrodes can be implanted under the skin and connect to internal stimulator electronics (22), which can form a magnetic inductive link to the external current source (34). Alternatively, the electrodes can be placed on the skin and directly linked by wires to the external current source. As a further alternative, the vagus nerve can be directly stimulated in the neck, or the esophagus, stomach, duodenum, or intestines can be directly stimulated by magnetic stimulation. The electrodes can stimulate the vagus nerve in the neck to reduce nausea and vomiting, or can be arranged near the chest or abdomen, so as to stimulate the esophagus, stomach, duodenum or intestines. Because the current source is provided outside the body, it is not necessary to implant batteries or another power supply in the body.

The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.

The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.

The present invention provides therapeutic formulations for solutions of DELTA9-tetrahydrocannabinol (DELTA9 THC) to be delivered by metered dose inhalers. The formulations, which use non-CFC propellants, provide a stable aerosol-deliverable source of DELTA9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy-muscle spasticity; pain; anorexia associated with AIDS wasting syndrome, epilepsy; glaucoma; bronchial asthma; and mood disorders.

The present invention provides therapeutic formulations for solutions of DELTA9-tetrahydrocannabinol (DELTA9 THC) to be delivered by metered dose inhalers. The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of DELTA9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy; muscle spasticity; pain; anorexia associated with AIDS wasting syndrome; epilepsy; glaucoma; bronchial asthma; and mood disorders.

Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.

The present invention includes a transdermal composition which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The composition may comprise the following components: a surfactant-lecithin organogel; and a cannabinoid. The composition may also comprise an exogenous terpene. The cannabinoid is capable of diffusing from the composition into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.

The invention discloses a new Chinese medicinal composition for treating medial headache and migraine and a preparation method thereof. The Chinese medicinal composition comprises the following raw material medicaments: szechuan lovage rhizome, root of red-rooted salvia, costustoot, fenugreek lysimachia, benzoin, tangerine peel, radix curcumae, cyperus rotunus, golden thread, baical skullcap root, cassia twig, incised notopterygium rhizome, angelica dahurlica, kudzuvine root, peach seed, safflower, common burreed rhizome, zedoary, pangolin scales, raw astragalus, radix paeoniae alba, red paeony root, tall gastrodia tuber, gambir plant, storax, grassleaf sweelflag rhizome, fineleaf schizonepeta herb, divaricate saposhnikovia root, radix ephedrae, weeping forsythia, manchurian wildginger, biond magnolia flower, mentha haplocalyx, raw rehmannia root, szechwan chinaberry fruit, rose, radix pseudo-ginseng, rosewood heart wood, garden burnet root, leonurus heterophyllus, cowherb seed, ground beeltle, sappan wood, dragon's blood, pinellia tuber and the like. The Chinese medicinal composition can be prepared into any oral administration preparation used commonly according to the conventional method of Chinese medicinal preparations. The Chinese medicinal composition can improve headaches of bitamporal, foreheads and orbital parts, pulsatile headache or boring pain and the like, and associated symptoms of nausea, vomiting, blurred vision, frequent micturition, urination disorder, stuffy nose, palpitation, hypertension, hypotension, arrhythmia, megrim, ataxia, diplopia, hearing loss, tinnitus, disturbance of consciousness and the like obviously, and has definite clinical effects, obvious curative effect and quick response. The Chinese medicinal composition of the invention is combined by adopting medicinal and edible medicaments formulated by National Formulary basically, and thus, the Chinese medicinal composition has the advantages of low cost and no toxic or side effect.

The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability.

A method of treating headache is provided using a water soluble magnesium salt. Specifically, a method of treating a headache is provided for an individual having a serum ionized magnesium concentration of 0.44 mmoles / L to 0.53 mmoles / L and having at least one headache symptom by administering an amount of a water soluble magnesium salt sufficaent to inhibit at least one headache symptom in the individual within 24 hours and to raise the serum ionized magnesium concentration in the individual to within a normal ionized magnesium concentration range of 0.54 mmoles / L to 0.67 mmoles / L. Headache symptoms which may be inhibited include: pain, aura, photophobia, nausea, unilateral pain and phonophobia.

A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates the adverse effects of urinary and / or fecal incontinence, nausea, bradycardia, bronchorrhea or brochospasm caused by the acetyl-cholinesterase inhibitors, without affecting the beneficial activity of the acetyl-cholinesterase inhibitors. This permits the administration of the optimum effective dosing of acetyl-cholinesterase inhibitors to provide maximum benefit to the patient with the added benefit of reducing or eliminating the unwanted side effects of fecal and urinary incontinence. Further, the combination of rivastigmine and glycopyrrolate has been effective in significantly improving cognitive function in patients suffering from acute dementia or cognitive impairment.

PCT No. PCT / SE96 / 01668 Sec. 371 Date Sep. 21, 1998 Sec. 102(e) Date Sep. 21, 1998 PCT Filed Dec. 18, 1996 PCT Pub. No. WO97 / 24068 PCT Pub. Date Jul. 10, 1997A measuring instrument for the measurement of an existing pain or a feeling of nausea of a patient. The measuring instrument induces pain in an arbitrary body part of said patient, by supplying an electrical current. The measuring instrument provides a current increase into said body part, until said induced pain is experienced by the patient as being as great as the existing pain / nausea. The current is supplied from a current source arranged in the measuring instrument via wires and electrodes, said electrodes being applied onto that part of the body in which pain is to be induced. When the pain induced is experienced to be as great as the existing pain / nausea, the body part is removed from the electrodes, whereupon a pain value is registered and shown on a display.

Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.

This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

The invention discloses a Chinese medicine composition for treating gastric ulcer and a preparation method thereof. The Chinese medicine composition is mainly formed by the following raw medicine materials: Poria cocos, coix seed, prepared frankincense, prepared myrrh, dalbergia wood, storax, rheum officinale, coptis, sangusis draconis, Rhizoma atractylodis, Mangnolia officinalis, fructus amomi, netmeg, Rhizoma atractylodis Macrocephalae, Chinese yam, Herba lycopi, charred catnip, charred Chinese arborvitae twig, dandelion, Mongolian snakegourd root, lightyellow sophora root, honeysuckle, lightyellow sophora root, white paeony root, Taraxacum officinale root, rhizoma cyperi and the like. The Chinese medicine composition of the invention can be prepared into any kind of common oral preparation according to the conventional Chinese medicine preparation method. The invention has the advantages that symptoms such as epigastralgia, ructus, acid regurgitation, heartburn, nausea, vomiting and the like are obviously improved, the clinical curative effect is exact, the curative effect is obvious and the rapid effect is obtained. Moreover, since the Chinese medicine composition is basically combined by homologous plant food medicines regulated in state pharmacopoeia, the cost is low, basically no toxic side effect exists and the like.

A method for treating a subject is provided, including receiving a sensor signal responsive to the subject eating, analyzing the sensor signal, and driving a current into tissue of the subject responsive to analyzing the signal. The current is typically driven into muscle tissue of the subject's stomach (20). Preferably, receiving the sensor signal includes sensing electrical potential change generated responsive to contraction of a muscle such as a stomach muscle of the subject. In a preferred embodiment, the sensor signal is analyzed with respect to the timing of ingestion, and a level of compliance of the subject with a desired ingestion schedule is determined. As appropriate, a parameter of the current driven into the tissue may be configured such that the application of the current to the tissue induces in the subject a sensation of satiation, discomfort, nausea, or vertigo.

S-alkylsiothiouronium derivatives such as S-ethylisothiouronium diethylphosphate are used for the treatment of headaches, in particular, migraines, as well as for the prevention or treatment of nausea and vomiting. The compositions of the invention are also effective in preventing or alleviating emesis associated with migraines or other medical conditions such as chemotherapy or radiotherapy, as well as other symptoms of migraines including phonophobia and photophobia.

A method for treating a subject is provided, including receiving a sensor signal responsive to the subject eating, analyzing the sensor signal, and driving a current into tissue of the subject responsive to analyzing the signal. The current is typically driven into muscle tissue of the subject's stomach (20). Preferably, receiving the sensor signal includes sensing electrical potential change generated responsive to contraction of a muscle such as a stomach muscle of the subject. In a preferred embodiment, the sensor signal is analyzed with respect to the timing of ingestion, and a level of compliance of the subject with a desired ingestion schedule is determined. As appropriate, a parameter of the current driven into the tissue may be configured such that the application of the current to the tissue induces in the subject a sensation of satiation, discomfort, nausea, or vertigo.

A method for the protection of a human being against any health impairment as a result of the ingestion of the whole or parts of a transdermal therapeutic system containing at least one pharmacologically active ingredient, which is toxic or induces nausea or addiction at oral, but not at transdermal administration is disclosed. The method comprises adding to said transdermal therapeutic system a substance being able to keep off a human being from said ingestion.

The present invention relates to a comfortable type removable tongue position corrective anti-snoring & anti-suffocating device. The device is made of wire or band material provided with suitable elasticity and rigidity, including at least a fixer, an upper force piece which is connected with the fixer and lower force piece. The device is mostly applied on upper jaw. The force end of the upper force piece is designed to be suitable to the normal configuration of the soft palate palatine, and acts on the portion in front of the sensitive position of the soft palate to raise up the soft palate palatine and uvula upward / upward and backward suitably without causing nausea and discomfort of peripheral tissue. The force end of the lower force piece is designed to be suitable to the normal configuration of the big tongue, and acts on the portion in front of the sensitive position of the posterior of the tongue to press the big tongue downward / front downward without causing discomfort and nausea. Thus, depending on the co-action of the upper and lower force piece, the blocked respiratory tract could be expanded to prevent snore and remit sleep apnea syndrome.

The Chinese medicine recipe for treating gastric diseases includes immature bitter orange, silktree albizia flower, rose, cuttle bone, bletilla tuber and other 19 kinds of Chinese medicinal materials in certain proportion. The present invention is used in improving via gastric disease symptoms, including stomachache, stomach distention, nausea, etc.

The invention relates to buccal tablets for preventing altitude stress and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine. The buccal tablets for preventing altitude stress comprises the following raw materials in parts by weight: 10-20 parts of rhodiola rosea, 8-15 parts of snow lotus herb, 3-8 parts of Chinese wolfberries, 6-10 parts of stigma croci, 3-7 parts of santalum album, 2-6 parts of lignum dalbergiae odoriferae, 2-6 parts of clove, 3-7 parts of fructus phyllanthi, 2-9 parts of strawberries, 5-11 parts of alpine radix codonopsis, 2-7 parts of radix glycyrrhizae, 3-5 parts of calculus bovis, 4-8 parts of moschus and 2-6 parts of indigo naturalis. According to the buccal tablets for preventing altitude stress provided by the invention, the various components supplement each other and are reasonable in compatibility, so that the buccal tablets can quickly eliminate symptoms of altitude stress, have the characteristics of having obvious curative effect, taking effect quickly and being not easy to relapse and is remarkable in curative effect in remitting symptoms of headache, palpitation, anhelation, appetite loss, lassitude, lack of power, dizziness, nausea, emesis and the like.

The invention discloses a traditional Chinese medicine composition for treating acute enteritis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following raw medicines: medicated leaven, malt, Alisma orientale, Poria, Rhizoma atractylodiss, Magnolia officinalis, Atractylodes macrocephaia, Chinese yam, coix seed, Amomum villosum, honeysuckle, dandelion, Chinese violet, plantain seed, gordon euryale seed, Limonitum, blighted wheat, Amomum cardamomum, cinnamon, nutgall, angelica, Ligustrum lucidum, cherokee rose and the like. The traditional Chinese medicine composition can be prepared into any one commonly used oral preparation according to the conventional method of traditional Chinese medicine preparations. The invention can obviously improve the symptoms of excessive diarrhea, loose stool, watery stool, abdominal pain, nausea, vomiting, dyspepsia, fever, body pain, limb weakness and the like, and has obvious clinical curative effect, significant curative effect and rapid effect. Since the traditional Chinese medicine composition adopts medicinal and edible medicines stipulated in the Chinese Pharmacopoeia to compound, the composition has the advantages of low cost, basically no toxicity and side effects and the like.

An anti-intoxication composition and method of making and using are provided for treating and preventing drinker's remorse and other toxic effects of excessive alcohol consumption by humans. The anti-intoxication composition is an acidic mixture containing sweeteners, flavoring agents, food additives and a processed mixture of metallic salts, sulfuric acid, ammonium sulfate and water. When the anti-intoxication composition is ingested, it promotes the beneficial metabolism of alcohol, primarily ethanol, in the body. The beneficial metabolism results in the conversion of alcohol to amino acids and eliminates the toxic reactions of a hangover, including, but not limited to, a pounding headache, nausea, dry mouth, shaking hands, hypersensitivity to bright lights and sounds.

The invention relates to a dragon and tiger rentan plant medicine composition, a preparation method and application thereof. The dragon and tiger rentan plant medicine composition comprises the following active components by weight proportions: 32-48g of menthol, 24-36g of borneol, 20-30g of cloves, 20-30g of villous amomum, 12-18g of star aniseeds, 32-48g of cinnamon, 12-18g of pepper, 12-18g ofcostus roots, 20-30g of dried ginger, 160-240g of catechu, 291.28-436.92g of glycyrrhiza, and the like. The preparation method comprises the following steps: preparing catechu pulp; and adding the mixed powder to prepare pills. The invention has short preparation period, low cost and good quality; and the dragon and tiger rentan plant medicine composition is used for preventing or treating heat stroke dizziness, nausea and vomiting, diarrhea, train and ship sickness, and the like.

Dosage regimens of buprenorphine achieving rapid pain relief without increasing nausea, vomiting, or other adverse effects, are described. Also described are buprenorphine dosage regimens for treating chronic pain comprising administering to the patient (1) a first buprenorphine-containing transdermal dosage form for a first dosing period that is no more than about 5 days; (2) a second buprenorphine-containing transdermal dosage form for a second dosing period that is no more than 5 days, the second dosage form comprising the same dosage of buprenorphine as, or a greater dosage of buprenorphine than, the first dosage form; and (3) a third buprenorphine-containing transdermal dosage form for a third dosing period, the third dosage form comprising a greater dosage of buprenorphine than the second dosage form.